ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2839

Effects Of Treatment On Spinal Fat Lesions As Assessed By MRI With The Fat Spondyloarthritis Spine Score

Susanne Juhl Pedersen1, Zheng Zhao2, Stephanie Wichuk3, Robert GW Lambert4 and Walter P. Maksymowych3, 1Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 2Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, 3Medicine, University of Alberta, Edmonton, AB, Canada, 4Radiology, University of Alberta, Edmonton, AB, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Magnetic resonance imaging (MRI), spondylarthritis and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Clinical and Imaging Aspects of Axial Spondyloarthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Fat lesions develop after resolution of inflammation in the spine (1), and have also been shown to predict development of new syndesmophytes (2). Consequently, spinal fat lesions may constitute an important measure of treatment efficacy and a surrogate for structural damage progression. The aim of this study was to investigate the effects of different treatments on development of fat lesions on spinal MRI.

Methods: A total of 135 patients with axial spondyloarthritis (SpA) had MRIs performed with a mean (SD) follow-up of 1.7 (0.8) years. Patients either received no anti-inflammatory treatment (n=12), or were treated with non-steroid anti-inflammatory drugs (NSAIDs) only (n=55), tumor-necrosis-factor-alpha (TNFα) inhibitor only (n=15) or NSAIDs and TNFα inhibitor in combination (n=53). Spinal fat lesions were assessed by the Fat Spondyloarthritis Spine Score (FASSS), where fat lesions are scored based on anatomical location and recorded dichotomously (present/absent) at each vertebral endplate (3). Scoring range per disco-vertebral unit (DVU) for the cervical spine is 0-8, and for the thoracic and lumbar spine: 0-24, resulting in a total score range of 0-456 for all 23 DVUs. Two rheumatologists evaluated pairs of scans blinded to clinical, biochemical or imaging data. Inter-class correlation coefficients were 0.96 (CI 95% 0.94-0.97) for baseline and 0.86 (0.80-0.90) for change scores.

Results: Patients treated only with NSAIDs had significantly shorter disease duration, lower CRP and structural damage on X-rays as assessed by mSASSS as compared to patients treated with TNFα inhibitor alone or in combination with NSAIDs (results not shown, Mann-Whitney test). Patients treated only with NSAIDs had lower FASSS at baseline (p=0.03) and had less change (p=0.01) as compared to patients treated only with TNFα inhibitors (Table 1). Furthermore, significantly more patients treated only with NSAIDs decreased or had no change in FASSS score during follow-up as compared to patients receiving no anti-inflammatory treatment (p=0.009) or TNFα inhibitor alone (p=0.03) (Table 1)(Chi2 test).

Conclusion: Treatment with NSAIDs is associated with a lower propensity to develop fat lesions which could be associated with their effects on new bone formation.

Table 1: FASSS baseline and change scores, and number and frequency of patients with decrease/no change or increase in FASSS scores stratified according to treatment.

 

FASSS scores

Change in FASSS score

Treatment group

Baseline

Change

Decreased/no change

Increased

1: No anti-inflammatory treatment   (n=12)

10.3 (0; 187)

2.0 (-1; 9.5)

2 (16.6)

10 (83.3)

2: NSAIDs only (n=55)

11.5 (0; 115)

0 (-9.5; 50)

32 (58.2)

23 (41.8)

3: TNFα inhibitor only (n=15)

18.5 (1; 118)

8.5 (-8; 51)

4 (26.7)

11 (73.3)

4: NSAIDs and TNFα inhibitor (n=53)

10.0 (0; 93)

1.5 (-35.5; 34)

21 (39.6)

32 (60.4)

Results are provided a median (range) or N (%).

References: 1. Chiowchanwisawakit et al. ARD 2010; 2. Chiowchanwisawakit et al. AR 2011; 3. Østergaard et al. J Rheum 2009


Disclosure:

S. J. Pedersen,
None;

Z. Zhao,
None;

S. Wichuk,
None;

R. G. Lambert,
None;

W. P. Maksymowych,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-treatment-on-spinal-fat-lesions-as-assessed-by-mri-with-the-fat-spondyloarthritis-spine-score/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology